TPST
NASDAQTempest Therapeutics
$2.05
+0.47 (+29.75%)
2026-04-10 00:00
Healthcare
Biotechnology
--
--
Short Interest (1 Year)
% of Volume Sold ShortMarket Cap
$22.4M
P/E Ratio
N/A
52W Low
52W High
$1.50
$12.23
Volume
1.7M
Analyst Rating
Hold
Target: $11
4 Analyst Ratings
Strong Buy
0
Buy
0
Hold
4
Sell
0
Price Target Range
Low: $11
Avg: $11
High: $11
About Tempest Therapeutics
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The comp...
Employees
4
Website
tempesttx.com
Financial Highlights
Annual
Quarterly
| Year | Revenue | Op Margin | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2025 | N/A | N/A% | -$26.3M | -$26.8M |
| 2024 | N/A | N/A% | -$41.8M | -$32.6M |
| 2023 | N/A | N/A% | -$29.5M | -$27.2M |
| 2022 | N/A | N/A% | -$35.7M | -$30.5M |
| 2021 | N/A | N/A% | -$28.3M | -$25.8M |
| 2025 Q4 | N/A | N/A% | -$4.0M | -$3.6M |
| 2025 Q3 | N/A | N/A% | -$3.5M | -$6.8M |
| 2025 Q2 | N/A | N/A% | -$7.9M | -$8.4M |
| 2025 Q1 | $486K | -2250.2% | -$10.9M | -$8.0M |
| 2024 Q4 | $486K | -2863.8% | -$13.8M | -$10.1M |
| 2024 Q3 | N/A | N/A% | -$10.6M | -$10.2M |
| 2024 Q2 | N/A | N/A% | -$9.6M | -$5.3M |
| 2024 Q1 | N/A | N/A% | -$7.9M | -$7.0M |